Corporate Information

(As of April 1, 2023)

Corporate Profile

Company Name	OAT Agrio Co., Ltd.
Head Office	8th Floor, NBF Ogawa-machi Bldg. 1-3-1 Kanda Ogawa-machi, Chiyoda-ku, Tokyo 101-0052, Japan TEL +81-3-5283-0251 FAX +81-3-5283-0258
Establishment	September 28, 2010
Capital	461.9 Million Yen
President	CEO Hisashi Oka
Business Domain	Research and development, manufacture and sale of agrochemicals and fertilizers
Number of Employees on consolidated basis	576(102) , as of December 31, 2022 *The numbers in parentheses are the average number of temporary employees

Business Location

Sapporo Sales Office	11th Floor, FUJIFILM Sapporo Bldg., 6-1, Odori Nishi, Chuo-ku, Sapporo-shi, 060-0042, Japan TEL +81-11-200-5151	Asi Ma
East Japan Branch Office	8th Floor, NBF Ogawa-machi Bldg. 1-3-1 Kanda Ogawa-machi, Chiyoda-ku, Tokyo 101-0052, Japan TEL +81-3-5283-0260	Dri Res
West Japan Branch Office	9th Floor, Honmachi Takeda Bldg. 3-1-29 Kyutaro-machi, Chuo-ku, Osaka-shi 541-0056, Japan TEL +81-6-6125-5355	Inp
West Japan Branch / Shikoku Office	12-1 Shimokubo, Himeda, Oasa-cho, Naruto-shi 779-0301, Japan TEL +81-88-684-4451	Lak Priv OA
Kyushu Sales Office	2-4-52 Shinhoka, Higashi-ku, Kumamoto-shi 862-0921, Japan TEL +81-96-360-5577	Lim Asi
Naruto Factory	615 Hanamen, Satoura, Satoura-cho, Naruto-shi 772-0021, Japan TEL +81-88-684-0210	PT.
Research & Development Division	615 Hanamen, Satoura, Satoura-cho, Naruto-shi 772-0021, Japan TEL +81-88-684-0201	Rur Pla
Cultivation Research Center	12-1 Shimokubo, Himeda, Oasa-cho, Naruto-shi 779-0301, Japan TEL +81-88-685-2890	LID
		Blu

Board of Directors


President, CEO	Hisashi Oka	
Director, Board Member, Senior Executive Officer	Satoshi Kitaguchi	Production Control Division, Research & Development Division
Director, Board Member, Senior Executive Officer	Wataru Okumura	Overseas Business Headquarters
Director, Board Member, Executive Officer	Hiroki Takase	General Affairs Division, Accounting Division, Intellectual Property & Legal Section
Director, Board Member, Executive Officer	Izumi Suemura	Domestic Business Headquarters
Director, Board Member, Executive Officer	Itoko Watanabe	Personnel Division, DX
Director (Audit & Supervisory Committee Member)	Minoru Kimura	(Outside Director)
Director (Audit & Supervisory Committee Member)	Jun Ogawa	(Outside Director)
Director (Audit & Supervisory Committee Member)	Motonori Araki	(Outside Director)
Executive Officer	Shigeuchi Toshiyuki	Director Business Development Division Overseas Business Headquarters
Executive Officer	Yoshihiro Fujimoto	Business Development Division Overseas Business Headquarters
Executive Officer	Kei Hidaka	Marketing & Technical Promotion Division Domestic Business Headquarters

Associated Companies

Asahi Chemical Manufacturing Co., Ltd	Establishment Address	February 9, 1952 500 Takayasu, Ikaruga-cho, Ikoma-gun, Nara TEL +81-745-74-1131 FAX +81-745-74-1961
	Main Domain	Manufacturing, sales, export/import of fertilizers and other products used in horticulture and agriculture
Drip Fertigation Research Co., Ltd.	Establishment Address	September 1, 2004 3-4-13, Higashi Ishioka, Ishioka-shi, Ibaraki TEL +81-299-56-6752 FAX +81-299-56-6753
	Main Domain	Sales of hydroponic cultivation systems and related products such as fertilizers
Inplanta Innovations Inc.	Establishment Address Main Domain	March, 2003 4-5-11, Namamugi, Tsurumi-ku, Yokohama-shi, Kanagawa Research and development of genetic engineering, and contracted research of plants, etc.
OAT&IIL India Laboratories Private Limited	Establishment Address	March, 2013 E-423, RIICO Industrial Area, Chopanki Bhiwadi -301707 Rajasthan, India
	Main Domain	Research and development of new crop protection products
OAT Pakistan Private Limited	Establishment Address	December, 2013 United Trade Centre, Office No-14, Gulshan-E-lqbal, Block-6, Main Rashid Minhas Road, Karachi, Sindh, Pakistan
	Main Domain	Import and sales of crop protection products
Asahi Chemical Europe s. r. o.	Establishment Address Main Domain	February, 2010 Lužná 716/2, 160 00 Praha 6 - Vokovice, Czech Republic Import and sales of crop protection products
PT. OAT MITOKU AGRIO	Establishment Address	January, 2016 JI. Taman Bendungan Asahan II No.8 Jakarta Pusat 10210, Indonesia
	Main Domain	Manufacturing and sales of agrochemicals and fertilizers
Runhe (Zhoushan) Plant Science Co., Ltd.	Establishment Address	May, 2016 Ruotiao Village, Xiushan Island, Daishan County, Zhoushan City, Zhejiang Province, P.R. of China.
	Main Domain	Manufacturing and sales of drip fertigation systems and fertilizers
LIDA Plant Research, S.L.	Establishment Address	1987 Parque Industrial Juan Carlos I - C/Granja,12-46440 ALMUSSAFES (Valencia)SPAIN
	Main Domain	Development, manufacturing, and sales of nutritional products and biostimulants and distribution of plant protection products
Blue Wave Holding B.V.	Establishment Address Main Domain	2014 (establishment of holding company) Gooimeer 7, 1411 DD Naarden P.O. Box.5300,1410 AH Naarden, The Netherlands Development, manufacturing and sale of post-harvest flower and plant care solutions

History

- **1950** Otsuka Pharmaceutical Factory divested the organic chemicals business to Otsuka Chemicals and Pharmaceuticals Co., Ltd.
- 1952 Started manufacturing and sales of agrochemicals
- **1953** Started selling a tobacco sucker inhibitor (OMH+30)
- 1963 Started selling gravel culture fertilizer
- 1964 Started selling the foliar fertilizer Samppi
- 1976 Started selling the herbicide Parazet
- 1979 Started selling the agricultural material disinfectant Ichiban, the insecticide Rubitocs and the molluscicide Namekit
- 1980 Started selling the fungicide Unitekt
- **1984** Changed the company name to Otsuka Chemical Co., Ltd.
- **1986** Started selling the herbicide Myzet and the insecticide
- **1992** Started selling the insecticide Oleate and the calcium supplement Calplus
- 1993 Started selling the insecticide Orion
- 1995 Started selling the insecticide Sted Granules
- 1996 Started selling the insecticide Ondaia
- **1997** Started selling the turf coloring agent Greenway
- **1998** Started selling Misaki for extending the life of cut flowers Started nationwide sales of the Drip Fertigation System
- **1999** Started selling Otsuka Judge Box Granules, an insecticide and fungicide specifically for rice seedling boxes
- 2000 Started selling the insecticides Grand Oncol, Oncol Micro Capsules, Ondaia Ace and Deraus Oncol Started selling the fungicide Alshine
- 2002 Otsuka Chemical Co., Ltd. was newly established to receive the chemical products and agrochemicals and fertilizer business Started selling the insecticide Hachi-Hachi EC
- 2007 Otsuka Chemical started selling the acaricide Danisaraba
- 2010 Established Otsuka AgriTechno Co., Ltd. and became independent from Otsuka Chemical Co., Ltd. by way of MBO
- 2011 Started the manufacturing and sales of the rice paddy herticides Benfuresate and Benzofenap which were acquired from the German company Bayer Crop Science
- 2012 Acquired Asahi Chemical Manufacturing Co., Ltd. as a 100% subsidiary
- 2013 Established OAT&IIL India Laboratories Private Limited based on an agreement with Insecticides (India) Limited Launched the fungicide Gatten in Japan
- 2014 Changed the company name to OAT Agrio Co., Ltd. Listed on the Second Section of Tokyo Stock Exchange
- 2015 Listed on The First Section of Tokyo Stock Exchange
- 2016 Established PT. OAT MITOKU AGRIO Established Runhe (Zhoushan) Plant Science Co., Ltd. Established OAT Agri Frontier Co., Ltd.
- 2017 Participate in establishment of Japan Generic Agrochemicals Association Started selling a new drip fertigation system "TT series" Acquired ISO 9001:2015 certification
- 2018 Established Japan Biostimulant Association as a founder Established H-New Corporation Acquired LIDA Plant Research, S.L. and CAPA Ecosystems, S.L. Acquired Inplanta Innovations Inc. as a 100% subsidiary Acquired Blue Wave Holding B.V including Chrysal and their associated companies
- 2019 Obtained EU pesticide registration approval for Flutianil Obtained GLOBAL GAP certificate
- 2020 Obtained California pesticide registration approval in USA
- 2022 Due to the revision of the market classification of the Tokyo Stock Exchange, Shifted from the First Section to Prime Market.




Financial Highlights (Consolidated)


ΑΟΑΤ9

(Unit: ¥ million)


	2018/12	2019/12	2020/12	2021/12	2022/12	
	15,278	21,909	20,288	22,678	26,960	
	6,968	9,389	9,464	10,707	12,660	
	1,743	1,077	1,512	2,001	3,346	
o owners of	1,261	4	837	1,456	2,261	
	30,684	29,724	28,848	28,346	31,009	
	7,532	6,807	7,632	9,096	11,949	









Total assets

















Management Indicators (Consolidated)






Note: The amount of total assets, inventory and fixed assets are calculated using the average of the figures at the beginning and end of the period.






Note: Net sales per employee, operating income per employee and net income per employee are calculated using the average number of employees during the period.



	2018/12	2019/12	2020/12	2021/12	2022/12
Free cash flow	△10,420	1,928	1,679	3,824	847
Capital expenditure	272	375	184	288	381
Depreciation and amortization	411	1,484	1,412	1,416	1,484

Note: Free cash flow= cash flows from operating activities + cash flows from investing activities

Other Investment Indicators/Indicators per share



	2010/12	2019/12	4
Return on equity (ROE) (%)	19.91	0.06	
Return on assets (ROA) (%)	8.13	2.77	
Net income per share (yen)	116.56	0.43	
Net assets per share (yen)	623.63	562.06	


Notes1: Shareholder's equity and total assets are calculated using the average of the figures at the beginning and end of the period. Notes2: Net income per share and net assets per share are retrospectively adjusted according to two for one stock split for shares of common stock on March 1, 2022.



Financial Statements (Consolidated)

2020/12	2021/12	2022/12
37.1	41.5	47.6
2.8	3.7	5.9
1.5	2.7	4.0
537	556	576
92	92	102

(Unit: %/yen)



	2021/12	2022/12
Assets		
Current assets		
Cash and deposits	3,651	3,614
Notes and accounts receivable- trade	5,275	_
Notes receivable - trade	_	452
Electronically recorded monetary claims - operating	-	62
Accounts receivable - trade	_	5,239
Merchandise and finished goods	2,682	3,443
Work in process	605	1,071
Raw materials and supplies	1,687	2,345
Other	664	750
Allowance for doubtful accounts	△54	△60
Total current assets	14,513	16,920
Non-current assets		
Property, plant and equipment		
Buildings and structures, net	1,222	1,176
Machinery, equipment and vehicles, net	698	745
Land	1,037	1,090
Leased assets, net	507	462
Other, net	242	303
Total property, plant and equipment	3,708	3,779
Intangible assets		
Goodwill	6,085	5,960
Software	98	184
Customer relation assets	2,651	2,650
Other	357	382
Total intangible assets	9,193	9,177
Investments and other assets		
Investment securities	370	428
Shares of subsidiaries and associates	74	82
Deferred tax assets	184	313
Other	301	307
Total investments and other assets	930	1,132
Total non-current assets	13,833	14,089
Fotal assets	28,346	31,009

· · · · · · · · · · · · · · · · · · ·	2021/12	2022/12
Liabilities		
Current liabilities		
Notes and accounts payable – trade	3,076	2,954
Short-term loans payable	4,728	5,865
Accounts payable - other	617	686
Income taxes payable	465	646
Provision for bonuses	33	37
Provision for loss on compensation for damage	21	23
Refund liabilities	105	128
Other	1,342	1,275
Total current liabilities	10,392	11,617
Non-current liabilities		
Long-term loans payable	7,401	5,951
Retirement benefit liability	161	282
Deferred tax liabilities	915	883
Other	379	324
Total non-current liabilities	8,858	7,442
Total liabilities	19,250	19,060
Net assets		
Shareholders' equity		
Capital stock	461	461
Capital surplus	2,404	2,410
Retained earnings	5,882	7,906
Treasury shares	△433	△408
Total shareholders' equity	8,314	10,371
Accumulated other comprehensive income		
Valuation difference on available- for-sale securities	83	72
Foreign currency translation adjustment	△172	632
Remeasurements of defined benefit plans	45	△44
Total accumulated other comprehensive income	△43	660
Non-controlling interests	825	917
Total net assets	9,096	11,949
Total liabilities and net assets	28,346	31,009

	2021/12	2022/1
Net sales	22,678	26,96
Cost of sales	11,971	14,29
Gross profit	10,707	12,66
Selling, general and administrative expenses	8,705	9,31
Operating income	2,001	3,34
Non-operating income		
Interest income	11	1
Dividend income	7	
Insurance fee income	29	3
Foreign exchange gains	82	15
Share of profit of entities accounted for using equity method	7	
Other	35	2
Total non-operating income	174	23
Non-operating expenses		
Interest expenses	171	18
Commission for purchase of treasury shares	2	
Other	13	1
Total non-operating expenses	186	19
Ordinary income	1,989	3,38
Extraordinary income		
Gain on sales of investment securities	78	-
Gain on sales of non-current assets	3	1
Gain on sale of businesses	234	-
Total extraordinary income	316	1
Extraordinary losses		
Loss on retirement of non-current assets	1	
Impairment loss	8	1
Loss on valuation of investment securities	18	-
Loss on valuation of shares of subsidiaries and associates	7	-
Total extraordinary losses	36	2
Profit before income taxes	2,269	3,37
Income taxes-current	838	1,19
Income taxes-deferred	△115	△18
Total income taxes	722	1,00
Profit	1,546	2,36
Profit attributable to non-controlling interests	89	10
Profit attributable to owners of parent	1,456	2,26

Pi	rofit
С	ther comprehensive i
	Valuation difference for-sale securities
	Foreign currency tran adjustment
	Remeasurements of plans, net of tax
С	omprehensive income
	Comprehensive inco attributable to
	Comprehensive inco to owners of parent
	Comprehensive incom non-controlling interes

Consolidated Balance Sheets

(Unit: ¥ million)

Consolidated Statements of Cash Flows (Unit: ¥ million)

	2021/12	2022/12
Cash flows from operating activities		
Profit before income taxes	2,269	3,378
Depreciation	825	864
Amortization of goodwill	591	620
Loss (gain) on sale of businesses	△234	-
Loss (gain) on valuation of investment securities	△78	-
Loss on sales of non-current assets	1	4
Loss (gain) on sales of non-current assets	∆3	△17
Impairment loss	8	19
Loss (gain) on valuation of investment securities	18	-
Share of loss (profit) of entities accounted for using equity method	△7	∆3
Insurance claim income	△29	△39
Interest and dividend income	△19	△19
Share-based remuneration expenses	22	32
Foreign exchange losses (gains)	10	△0
Interest expenses	171	182
Increase (decrease) in net defined benefit liability	△121	120
Increase (decrease) in allowance for doubtful accounts	△2	1
Increase (decrease) in refund liability	△22	22
Increase (decrease) in provision for bonuses	2	3
Decrease (increase) in trade receivables	204	△306
Decrease (increase) in inventories	△429	△1,698
Increase (decrease) in trade payables	996	△216
Increase (decrease) in accounts payable-other	13	△43
Other, net	131	△330
Subtotal	4,320	2,575
Interest and dividends received	24	3
Interest paid	△173	△153
Compensation for damage paid	△25	
Income taxes paid	△570	△1,048
Proceeds from insurance income	29	39
Net cash provided by (used in) operating activities	3,603	1,416
Cash flows from investing activities	-,	.,
Payments into time deposits	△390	△106
Proceeds from withdrawal of time deposits	476	-
Purchase of property, plant and equipment	△259	△288
Proceeds from sales of property, plant and equipment	6	19
Purchase of intangible assets	△146	△120
Proceeds from sales of investment securities	288	_
Purchase of sales of investment securities		△73
Proceeds from sales of shares of subsidiaries and associates	12	
Proceeds from sale of businesses	234	_
Other. net	0	
Net cash provided by (used in) investing activities	221	
Cash flows from financing activities	221	
Net increase (decrease) in short-term loans payable	△1,801	811
Proceeds from long-term borrowings		1,678
Repayments of long-term borrowings	△1,416	△3,045
Repayments of lease obligations	△1,410	△171
Purchase of treasury shares	△140	
Dividends paid	△299	△237
	△215	△237
Dividends paid to non-controlling interests Other, net	 	
Net cash provided by (used in) financing activities	△3,936	<u>∧1020</u>
		△1,029 38
Effect of exchange rate change on cash and cash equivalents	97 ^ 12	38
Net increase (decrease) in cash and cash equivalents	△12 2.5.27	△143 2 5 1 4
Cash and cash equivalents at beginning of period	3,527	3,514
Cash and cash equivalents at end of period	3,514	3,371

Consolidated Statements of Income (Unit: ¥ million)

Consolidated Statements of Comprehensive Income (Unit: ¥ million)

	2021/12	2022/12
	1,546	2,369
ncome	511	756
on available-	△6	△11
slation	430	858
defined benefit	87	△89
	2,057	3,126
ne		
ne attributable	1,922	2,966
e attributable to ts	135	160